Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. Issue 3 (13th March 2013)
- Record Type:
- Journal Article
- Title:
- Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. Issue 3 (13th March 2013)
- Main Title:
- Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study
- Authors:
- Hilliard, P.
Zourikian, N.
Blanchette, V.
Chan, A.
Elliott, B.
Israels, S. J.
Nilson, J.
Poon, M.‐C.
Laferriere, N.
Van Neste, C.
Jarock, C.
Wu, J.
McLimont, M.
Feldman, B. - Abstract:
- <abstract abstract-type="main" xml:lang="en" id="jth12113-abs-0001"> <title>Summary</title> <sec id="jth12113-sec-0001" sec-type="section"> <title>Background</title> <p>Full‐dose prophylaxis is very effective at minimizing joint damage but is costly. Tailored prophylaxis has been proposed as a way of reducing costs while still protecting joints.</p> </sec> <sec id="jth12113-sec-0002" sec-type="section"> <title>Objective</title> <p>To report detailed findings in index joints of 56 subjects with severe hemophilia A entered into the Canadian Hemophilia Prophylaxis Study, and treated with tailored prophylaxis, after 13 years.</p> </sec> <sec id="jth12113-sec-0003" sec-type="section"> <title>Methods</title> <p>Boys with severe hemophilia A (&lt; 2% factor) and normal joints were enrolled between the ages of 1 and 2.5 years. Initial treatment consisted of once‐weekly factor infusions, with the frequency escalating in a stepwise fashion when breakthrough bleeding occurred. During the first 5 years, subjects were examined every 3 months using the modified Colorado Physical Evaluation (PE) scale; subsequently, every 6 months. The Childhood Health Assessment Questionnaire (CHAQ) was administered at each visit.</p> </sec> <sec id="jth12113-sec-0004" sec-type="section"> <title>Results</title> <p>Median age at study entry was 19 months (range 12–30 months); median follow‐up was 92 months (range 2–156). The median PE score was 2, 3 and 3 at ages 3, 6 and 10 years. Persistent findings were<abstract abstract-type="main" xml:lang="en" id="jth12113-abs-0001"> <title>Summary</title> <sec id="jth12113-sec-0001" sec-type="section"> <title>Background</title> <p>Full‐dose prophylaxis is very effective at minimizing joint damage but is costly. Tailored prophylaxis has been proposed as a way of reducing costs while still protecting joints.</p> </sec> <sec id="jth12113-sec-0002" sec-type="section"> <title>Objective</title> <p>To report detailed findings in index joints of 56 subjects with severe hemophilia A entered into the Canadian Hemophilia Prophylaxis Study, and treated with tailored prophylaxis, after 13 years.</p> </sec> <sec id="jth12113-sec-0003" sec-type="section"> <title>Methods</title> <p>Boys with severe hemophilia A (&lt; 2% factor) and normal joints were enrolled between the ages of 1 and 2.5 years. Initial treatment consisted of once‐weekly factor infusions, with the frequency escalating in a stepwise fashion when breakthrough bleeding occurred. During the first 5 years, subjects were examined every 3 months using the modified Colorado Physical Evaluation (PE) scale; subsequently, every 6 months. The Childhood Health Assessment Questionnaire (CHAQ) was administered at each visit.</p> </sec> <sec id="jth12113-sec-0004" sec-type="section"> <title>Results</title> <p>Median age at study entry was 19 months (range 12–30 months); median follow‐up was 92 months (range 2–156). The median PE score was 2, 3 and 3 at ages 3, 6 and 10 years. Persistent findings were related to swelling, muscle atrophy and loss of range of motion. The median score for each of these items (for the six index joints) was 0 at ages 3, 6 and 10 years. The median overall CHAQ score was 0 at ages 3, 6 and 10 years, indicating excellent function.</p> </sec> <sec id="jth12113-sec-0005" sec-type="section"> <title>Conclusions</title> <p>Canadian boys treated with tailored primary prophylaxis exhibit minimal joint change on physical examination and minimal functional disability.</p> </sec> </abstract> … (more)
- Is Part Of:
- Journal of thrombosis and haemostasis. Volume 11:Issue 3(2013)
- Journal:
- Journal of thrombosis and haemostasis
- Issue:
- Volume 11:Issue 3(2013)
- Issue Display:
- Volume 11, Issue 3 (2013)
- Year:
- 2013
- Volume:
- 11
- Issue:
- 3
- Issue Sort Value:
- 2013-0011-0003-0000
- Page Start:
- 460
- Page End:
- 466
- Publication Date:
- 2013-03-13
- Subjects:
- Thrombosis -- Periodicals
Hemostasis -- Periodicals
Blood coagulation disorders -- Periodicals
616.1 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836 ↗
http://www.blackwellpublishing.com/journals/jth ↗
https://www.sciencedirect.com/journal/journal-of-thrombosis-and-haemostasis ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/jth.12113 ↗
- Languages:
- English
- ISSNs:
- 1538-7933
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5069.345000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3757.xml